Navigation Links
Grupo IMO Hosts Symposium on Use of TomoTherapy for Stereotactic Radiosurgery and Stereotactic Body Radiation Procedures : Experts Detail HiArt Platform Advantages for Treatment of Brain, Lung, Pancreatic and Metastatic Cancers
Date:10/15/2008

TomoTherapy Incorporated (NASDAQ: TOMO) announced today that Grupo IMO of Madrid, Spain, recently hosted a symposium on the clinical use of the HiArt treatment system for stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT). Symposium speakers highlighted the HiArt system’s inherent suitability for stereotactic procedures with respect to dose conformality and homogeneity; presented clinical work on a variety of intra- and extracranial cases; and discussed future research goals.

MADISON, Wis. (Business Wire EON) October 15, 2008 -- According to Jef Van Dam, TomoTherapy EMEA General Manager: "We are extremely pleased that Grupo IMO hosted this symposium highlighting the excellent clinical stereotactic work being done by TomoTherapy customers. We are eager to demonstrate how the clinical applications of TomoTherapy continue to grow as new treatment possibilities are explored by our clinical partners."

The 'Symposium on Tomo-Radiosurgery' included presentations from Dr. Jos Sambls, neurosurgeon and Grupo IMO president, Dr. Jos Miguel Delgado, clinical physicist and technical director for Grupo IMO, and Dr. Matthias Uhl, radiation oncologist, Heidelberg University Clinic, Heidelberg, Germany. The event was held in conjunction with the Spanish Radiosurgery Conference.

Peter Hoban, Ph.D., TomoTherapy senior product managerand medical physicist, began the program by outlining features that make the HiArt system ideal for providing stereotactic treatments: "TomoTherapy's integrated imaging and delivery platform allows one simple process to be used for both stereotactic and intensity-modulated radiation therapy (IMRT) treatments. The system clearly lends itself to a diverse range of clinical indications, as evidenced by the presentations of Drs. Sambls, Delgado and Uhl."

  • Sambls and Dr. Delgado presented technical and clinical stereotactic work using the TomoTherapy HiArt treatment system and discussed Grupo IMO's research goals for the future.

Said Dr. Sambls: "TomoTherapy HiArt allows the development of new techniques for treating brain tumors with maximum precision. In this sense, we have achieved great preliminary results with what we call Tomo-Radiosurgery, fundamentally with regard to irregularly shaped brain tumors, brain metastases and tumors located close to critical organs such as the optic nerves and the brain stem. Another example is the treatment of acoustic neurinoma. We believe TomoTherapy's especially homogenous dose distribution capabilities may help to spare sensitive auditory nerve tissue."

  • Matthias Uhl explained how University Clinic Heidelberg has expanded its own use of the TomoTherapy HiArt system to include stereotactic treatments.

"We are applying TomoTherapy to SBRT for early-stage lung cancer and also multiple metastases in the brain and liver," said Dr. Uhl. "Treating multiple lesions simultaneously results in a reduced amount of timethe patient spends in the treatment room compared with conventional treatment alternatives."

About Grupo IMO

Grupo IMO is the first facility in Spain to offer TomoTherapy radiation treatments. More than 300 patients have been treated on the TomoTherapy HiArt System since April 2006. Established in 1991, Grupo IMO has the largest autonomous network of ten reference centers for cancer treatment using radiotherapy and radiosurgery techniques in Spain.

About TomoTherapy Incorporated

TomoTherapy Incorporated has developed, markets and sells the TomoTherapy HiArt treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The HiArt treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company's stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

2008 TomoTherapy Incorporated. All rights reserved.TomoTherapy, the TomoTherapy logo and HiArt are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated.

Read the full story at http://www.prweb.com/releases/grupo_imo/stereotactic_body/prweb1480034.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Grupo Casa Saba Announces Sales and Operating Income Increased 14.05% and 13.45%, Respectively
2. Grupo Casa Saba Announces Fourth Quarter 2007 Results
3. Grupo Casa Saba Announces Third Quarter 2007 Results
4. Pennsylvania Breast Cancer Coalition Hosts Annual Conference
5. Baird Hosts Small Cap Health Care Conference : Senior Healthcare Distribution & Services Research Analyst Eric Coldwell Shares Insights on Sector
6. Health Insurance Industry Hosts Roundtable Discussion on Health Care Reform in Albuquerque
7. RMA of Michigan Hosts 1st Metro Detroit Area Hope Uncorked: Exclusive Wine Tasting Event To Benefit Fertile Hope
8. Alameda County Hosts National Initiative to Reduce Health Disparities
9. Hospira Hosts Conference Call for Second-Quarter 2008 Earnings
10. National Medical Association Hosts the 2008 Annual Convention and Scientific Assembly
11. Bioniche Hosts Veterinarians and Food Industry Reps at Two-Day E. coli O157:H7 Vaccine Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 Grupo IMO Hosts Symposium on Use of TomoTherapy for Stereotactic Radiosurgery and Stereotactic Body Radiation Procedures :  Experts Detail HiArt Platform Advantages for Treatment of Brain, Lung, Pancreatic and Metastatic Cancers 
(Date:2/24/2017)... ... 2017 , ... Houston dentist , Dr. Behzad Nazari, ... Center. Currently, patients can get single dental implants for $3,599 and All On ... more about these offers by contacting Antoine Dental Center. Both of these options ...
(Date:2/24/2017)... , ... February 24, 2017 , ... The Smart Machine ... from Oxford University predict that 47 percent of all jobs in the United States ... “smart” and “successful.” The day of the aggressive know-it-all who steamrolls over colleagues is ...
(Date:2/24/2017)... ... February 24, 2017 , ... With ProGlass Prism users now have the ... have total control over position, rotation, distortion, edge softness, edge blur, chromatic aberration, individual ... X. , With ProGlass Prism users are given the tools and effects to ...
(Date:2/24/2017)... ... February 24, 2017 , ... The Radiology Business Management Association will ... at the annual Building Better Radiology Marketing Programs conference, held this year ... Worth, Texas. Nine awards are given out in five categories. They are:, ...
(Date:2/23/2017)... MA (PRWEB) , ... February 23, 2017 , ... ... and Department of Justice jointly issued a letter to withdraw previous ... accordance with their gender identity. The guidance issued in May 2016 by the ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... and Markets has announced the addition of the "Dry eye Drugs ... ... Drugs Price Analysis and Strategies - 2016, provides drug pricing data and ... following questions: What are the key drugs ... in the Global Dry eye market? What are the ...
(Date:2/24/2017)... CHAPEL HILL, N.C. , Feb. 24, 2017 ... sector are exploring ways to increase their self-service ... as Health Care Providers (HCPs). New ... that many pharma organizations have developed self-service website ... questions electronically.  This is just one of many ...
(Date:2/24/2017)... 2017 Report analyzes the worldwide markets for Endodontic ... for the US, Canada , ... Asia-Pacific , Latin America , and ... the period 2015 through 2022. Also, a six-year historic analysis ... derived from primary and secondary research. Company profiles are primarily ...
Breaking Medicine Technology: